OralogiK Lead BDD’s proprietary OralogiK delayed release technology enables targeted colon delivery and site-specific release profiles, presenting a compelling opportunity to position partnerships for late-stage drug delivery optimization and new formulation development.

Clinical Acceleration Their rapid parallel clinical testing capability and full clinical package including protocol design, regulatory submission, and ICH GCP-compliant study reporting suggest a strong value proposition for CRO partnerships and sponsor-ready study support to shorten development timelines.

Gamma Scintigraphy BDDs expertise in gamma scintigraphy combined with pharmacokinetic data offers a differentiator for in vivo formulation validation, enabling collaborations for complex release profiles, bioavailability studies, and translational research with pharma companies.

Growth & Funding With revenue in the mid single digits and recent funding activity, there is potential to engage in co-development or venture-backed programs aimed at expanding the OralogiK platform and scaling manufacturing capabilities for new partners.

Global Partners Recent collaborations and leadership appointments indicate an openness to strategic partnerships; approach potential pharma and biotech partners seeking modified-release expertise, coating technology, or lifecycle management to extend product portfolios.